STENTYS

Financial Information for the Third Quarter of 2019 - Seite 2

+8%

Audited data

STENTYS completed the acquisition of MINVASYS during the second quarter of 2018, its activity being consolidated from May 1, 2018. The changes presented for the first 9 months of 2019 are therefore partly due to different scopes of consolidation. The following pro forma information thus provides a vision of revenue changes on a comparable basis.

Pro forma revenues for the first 9 months of 2019

€ thousands	9M 2019	9M 2018 Pro forma3	% change
Europe2	3,771	4,115	-8%
Rest of the world	2,625	3,662	-28%
Total revenues	6,396	7,777	-18%

Audited data (except pro forma information)

€ thousands	9M 2019	9M 2018 Pro forma3	% change
Stents	3,512	4,972	-29%
Balloons & accessories	2,884	2,806	+3%
Total revenues	6,396	7,777	-18%

Audited data (except pro forma information)

Over the first 9 months of 2019, the Group generated revenues of €6.4 million, down 18% compared with the first 9 months of 2018 (pro forma¹), heavily impacted by a 41% fall in the third quarter of 2019 compared with the third quarter of 2018.

Within the framework of a CE marking renewal process, the Company received a request from the French health authorities on August 2, 2019, following the announcement of its planned early dissolution, to suspend sales of its Amazonia SIR stent within the framework of a transitional regulatory provision. On October 7, 2019, the Company was authorized to resume sales of this product until January 8, 2020. Amazonia SIR stent sales thus tumbled 89% in the 3^rd quarter of 2019.